The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” ...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now ...